盐酸羟考酮控释片治疗中重癌痛76例的临床观察  

Clinical Study of Controlled-release Oxycodon on Treatment of 76 Cases with Moderate and Sever Pain Caused by Cancer

作　　者：何莹[1] 何陵湘[1] 

机构地区：[1]广东省农垦中心医院,广东湛江524002

出　　处：《今日药学》2008年第4期50-51,共2页Pharmacy Today

摘　　要：目的观察盐酸羟考酮控释片对中、重度癌痛患者的止痛效果及不良反应。方法76例中、重度癌痛患者口服盐酸羟考酮控释片片,记录治疗前后的疼痛强度、生活质量评分及不良反应。结果76例中重度癌痛患者,轻度缓解3例(3.9%),中度缓解9例(11.8%),明显缓解39例(51.3%),完全缓解25例(32.9%),中、重度癌痛的镇痛有效率为96.1%(73/76),其中显著有效率(完全+中度缓解)为89.5%(68/76)。治疗前疼痛级数8.2±1.6,治疗后3.3±1.5,(P<0.05)。治疗前平均KPS评分41±11,治疗后70±13,生活质量治疗后较治疗前明显改善(P<0.05)。不良反应主要为便秘28例(36.8%)。结论盐酸羟考酮控释片能有效控制癌性疼痛,改善生活质量,且不良反应轻微,发生率低。Objective to observe the analgesic effect and the adverse effect of controlled-release oxycodon in management of the moderate and severe cancer pain. Methods A total of 76 cases with moderate and severe cancer pain were treated with controlledrelease oxycodon tablets. Evaluated outcomes included analgesic effect, scales of the functional assessment of quality of life, and side effects. Results Among all the 76 patients suffering moderate and severe cancer pain, 3 （3.9%） achieved slightly pain relief. The moderate, obvious, and complete pain relief occurred in 9 （11.8%）, 39 （51.3%）, and 25 （32.9%） patients, respectively. The pain was alleviated affter treatment, pain grade 3.3±1.5 was smaller then before （pain grade 8.2±1.6, P〈0.05）. Additionally, the patients had a significant superior activity for living quality. The karnofsky mark after treatment 70±13 was higher then before 41±11 （P〈0.05）. Main adverse effect was constipation in 28 patients （36.8%）. Conclusion The controlled-release oxycodon can effectively control cancer pain, improve the living quantity, and has comparatively slight adverse effects.

关 键 词：盐酸羟考酮控释片 癌痛 镇痛剂 

分 类 号：R97[医药卫生—药品]